AstraZeneca plc (NYSE: AZN) can heave a sigh of relief following resumption of its coronavirus vaccine study that was voluntarily paused by the company.What Happened: The U.K. pharma giant said U.K. regulatory agency, the Medicines Health Regulatory Authority (MHRA) has given its concurrence to resume the late-stage study of AZD1222 — the vaccine candidate it is jointly developing with the Oxford University against SARS-CoV-2.Following a standard review process, AstraZeneca paused all global trials on Sept. 6 after an unidentified illness was reported in one of the trial participants. The company later clarified that the person was a …read more
Source:: Yahoo Finance
